Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Chemotherapy-induced Neutropenia × Drug Therapy × Clear all

Phase

Phase 3 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 21 Breast Neoplasms 17 Colorectal Neoplasms 13 Ovarian Neoplasms 11 Lung Neoplasms 10 Neoplasm Metastasis 9 Stomach Neoplasms 8 Nasopharyngeal Carcinoma 8 Neoplasms 7 Leukemia, Myeloid, Acute 7 Squamous Cell Carcinoma of Head and Neck 6 Rectal Neoplasms 6 Recurrence 5 Precursor Cell Lymphoblastic Leukemia-Lymphoma 5 Fallopian Tube Neoplasms 5 Esophageal Squamous Cell Carcinoma 5 Uterine Cervical Neoplasms 4 Triple Negative Breast Neoplasms 4 Prostatic Neoplasms 4 Leukemia 4 Head and Neck Neoplasms 4 Esophageal Neoplasms 4 Pancreatic Neoplasms 3 Neoplasms by Site 3 Lymphoma, Non-Hodgkin 3 Carcinoma, Ovarian Epithelial 3 Adenocarcinoma 3 Urinary Bladder Neoplasms 2 Multiple Myeloma 2 Melanoma 2

Interventions

pegfilgrastim 3 NPI 2358 2 Granulocyte Colony-Stimulating Factor 2 Doxorubicin 2 Docetaxel 2 balugrastim 1 Drug Therapy 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01126190 2023-03-28

NEUGR-003

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 3 Completed

381 enrolled 13 charts

Chemotherapy-induced Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡